Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is expected to experience continued growth in 2026, driven by increasing penetration in open ablation, minimally invasive ablation, and pain management products, as well as the adoption of its EnCompass clamp as a quality metric for cardiac surgery. Additionally, the recent launch of its cryoSPHERE MAX probe for pain management has received positive feedback, contributing to strong sales in this segment. With a strong balance sheet and a focus on innovation, AtriCure is well-positioned to compete with potential competitors, such as Edwards Lifesciences.

Bears say

AtriCure is facing threats to sales from new competitors, such as Edwards Lifesciences, launching their own surgical left atrial appendage closure device later this year and possibly causing market share loss and slower margin improvement. In addition, there is a risk of weaker sales and slower earnings growth due to potential unmet patient needs. Furthermore, AtriCure may see slower free cash flow if sales are not meeting expectations.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.